(FII) Lisi S.A - Overview
Fasteners, Implants, Brakes, Fittings, Stapler
Dividends
| Dividend Yield | 1.41% |
| Yield on Cost 5y | 2.20% |
| Yield CAGR 5y | 29.19% |
| Payout Consistency | 91.7% |
| Payout Ratio | 28.9% |
| Risk 5d forecast | |
|---|---|
| Volatility | 33.5% |
| Relative Tail Risk | -9.99% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.96 |
| Alpha | 92.96 |
| Character TTM | |
|---|---|
| Beta | 0.132 |
| Beta Downside | 0.382 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.50% |
| CAGR/Max DD | 1.27 |
Description: FII Lisi S.A January 13, 2026
LISI S.A. (PA:FII) is a French-based designer and manufacturer of high-precision assembly and component solutions serving the aerospace, automotive, and medical sectors worldwide. The firm operates through three distinct business units-LISI Aerospace, LISI Automotive, and LISI Medical-each supplying specialized fasteners, hydraulic fittings, sealing components, and minimally invasive surgical instruments such as staplers and hip prostheses.
In FY 2023 the company reported revenue of roughly €1.5 billion, with an EBIT margin of 6 % and R&D expenditure representing about 5 % of sales, reflecting its focus on engineering-intensive product lines. The order backlog stood at approximately 1.2 × annual revenue, indicating a solid pipeline but also exposing LISI to the cyclicality of aerospace demand, which is closely linked to airline capacity growth and defense procurement budgets.
Key macro-drivers for LISI include the ongoing recovery in commercial aviation post-COVID, the automotive industrys shift toward electric vehicles (which can reduce demand for traditional fasteners while creating new opportunities in high-voltage system components), and demographic trends that sustain growth in medical implants and minimally invasive devices. A sensitivity analysis suggests that a 5 % swing in aerospace OEM orders would move EBIT by ±0.8 percentage points, underscoring the importance of diversification across its three segments.
For a deeper quantitative dive, the ValueRay platform offers a granular view of LISI’s financials and peer benchmarks.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 118.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 7.44 > 1.0 |
| NWC/Revenue: 10.41% < 20% (prev 13.55%; Δ -3.14% < -1%) |
| CFO/TA 0.14 > 3% & CFO 323.5m > Net Income 118.6m |
| Net Debt (519.7m) to EBITDA (440.0m): 1.18 < 3 |
| Current Ratio: 1.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (46.5m) vs 12m ago 0.85% < -2% |
| Gross Margin: 38.13% > 18% (prev 0.03%; Δ 3810 % > 0.5%) |
| Asset Turnover: 167.4% > 50% (prev 110.5%; Δ 56.86% > 0%) |
| Interest Coverage Ratio: 2.95 > 6 (EBITDA TTM 440.0m / Interest Expense TTM 85.0m) |
Altman Z'' 2.72
| A: 0.16 (Total Current Assets 1.05b - Total Current Liabilities 672.0m) / Total Assets 2.28b |
| B: 0.02 (Retained Earnings 38.5m / Total Assets 2.28b) |
| C: 0.12 (EBIT TTM 250.4m / Avg Total Assets 2.16b) |
| D: 0.77 (Book Value of Equity 997.0m / Total Liabilities 1.30b) |
| Altman-Z'' Score: 2.72 = A |
Beneish M -3.98
| DSRI: 0.52 (Receivables 227.4m/273.9m, Revenue 3.61b/2.25b) |
| GMI: 0.09 (GM 38.13% / 3.32%) |
| AQI: 0.88 (AQ_t 0.22 / AQ_t-1 0.25) |
| SGI: 1.61 (Revenue 3.61b / 2.25b) |
| TATA: -0.09 (NI 118.6m - CFO 323.5m) / TA 2.28b) |
| Beneish M-Score: -3.98 (Cap -4..+1) = AAA |
What is the price of FII shares?
Over the past week, the price has changed by -0.92%, over one month by +3.87%, over three months by +7.40% and over the past year by +104.02%.
Is FII a buy, sell or hold?
What are the forecasts/targets for the FII price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 54.4 | 1.2% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 66.8 | 24.4% |
FII Fundamental Data Overview January 28, 2026
P/E Trailing = 41.1852
P/E Forward = 9.8717
P/S = 1.3142
P/B = 2.5721
Revenue TTM = 3.61b EUR
EBIT TTM = 250.4m EUR
EBITDA TTM = 440.0m EUR
Long Term Debt = 427.5m EUR (from longTermDebt, last quarter)
Short Term Debt = 254.6m EUR (from shortTermDebt, last quarter)
Debt = 774.9m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 519.7m EUR (from netDebt column, last quarter)
Enterprise Value = 3.06b EUR (2.54b + Debt 774.9m - CCE 255.2m)
Interest Coverage Ratio = 2.95 (Ebit TTM 250.4m / Interest Expense TTM 85.0m)
EV/FCF = 21.54x (Enterprise Value 3.06b / FCF TTM 142.1m)
FCF Yield = 4.64% (FCF TTM 142.1m / Enterprise Value 3.06b)
FCF Margin = 3.93% (FCF TTM 142.1m / Revenue TTM 3.61b)
Net Margin = 3.28% (Net Income TTM 118.6m / Revenue TTM 3.61b)
Gross Margin = 38.13% ((Revenue TTM 3.61b - Cost of Revenue TTM 2.23b) / Revenue TTM)
Gross Margin QoQ = 50.94% (prev 43.67%)
Tobins Q-Ratio = 1.34 (Enterprise Value 3.06b / Total Assets 2.28b)
Interest Expense / Debt = 1.70% (Interest Expense 13.1m / Debt 774.9m)
Taxrate = 25.79% (13.5m / 52.2m)
NOPAT = 185.8m (EBIT 250.4m * (1 - 25.79%))
Current Ratio = 1.56 (Total Current Assets 1.05b / Total Current Liabilities 672.0m)
Debt / Equity = 0.79 (Debt 774.9m / totalStockholderEquity, last quarter 977.6m)
Debt / EBITDA = 1.18 (Net Debt 519.7m / EBITDA 440.0m)
Debt / FCF = 3.66 (Net Debt 519.7m / FCF TTM 142.1m)
Total Stockholder Equity = 967.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.49% (Net Income 118.6m / Total Assets 2.28b)
RoE = 12.25% (Net Income TTM 118.6m / Total Stockholder Equity 967.8m)
RoCE = 17.94% (EBIT 250.4m / Capital Employed (Equity 967.8m + L.T.Debt 427.5m))
RoIC = 13.11% (NOPAT 185.8m / Invested Capital 1.42b)
WACC = 5.20% (E(2.54b)/V(3.32b) * Re(6.40%) + D(774.9m)/V(3.32b) * Rd(1.70%) * (1-Tc(0.26)))
Discount Rate = 6.40% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 0.42%
[DCF Debug] Terminal Value 87.06% ; FCFF base≈142.1m ; Y1≈153.3m ; Y5≈188.8m
Fair Price DCF = 110.8 (EV 5.59b - Net Debt 519.7m = Equity 5.07b / Shares 45.7m; r=5.90% [WACC]; 5y FCF grow 8.88% → 2.90% )
EPS Correlation: -8.69 | EPS CAGR: -43.90% | SUE: 0.0 | # QB: 0
Revenue Correlation: 94.71 | Revenue CAGR: 26.62% | SUE: 0.04 | # QB: 0
EPS next Year (2026-12-31): EPS=2.60 | Chg30d=+0.013 | Revisions Net=+0 | Growth EPS=+29.9% | Growth Revenue=+6.7%